Literature DB >> 27457874

[Guidelines for vaccination of immunocompromised individuals].

Ursula Wiedermann1, Harald H Sitte2, Heinz Burgmann3, Alexander Eser4, Petra Falb5, Heidemarie Holzmann6, Maria Kitchen7, Marcus Köller8, Herwig Kollaritsch9, Michael Kundi10, Hans Lassmann11, Ingomar Mutz12, Winfried F Pickl13, Elisabeth Riedl14, Maria Sibilia15, Florian Thalhammer3, Barbara Tucek5, Werner Zenz16, Karl Zwiauer17.   

Abstract

Immunosuppression of various origins is associated with an increased risk of infection; therefore the prevention of infectious diseases by vaccination is especially important in immunocompromised patients. However, the response to vaccinations is often reduced in these risk groups and the application of live vaccines is contraindicated during immunosuppression.In the following expert statement, recommendations for vaccination were created on the basis of current evidence and theoretical/immunological considerations. A first, general part elaborates on efficacy and safety of vaccinations during immunosuppression, modes of action of immunosuppressive medications and recommended time intervals between immunosuppressive treatments and vaccinations. A core piece of this part is a graduation of immunosuppression into three stages, i. e. no relevant immunosuppression, mild to moderate and severe immunosuppression and the assignment of various medications (including biologicals) to one of those stages; this is followed by an overview of possible and necessary vaccinations in each of those stages.The second part gives detailed vaccination guidelines for common diseases and therapies associated with immunosuppression. Primary immune deficiencies, chronic kidney disease, diabetes mellitus, solid and hematological tumors, hematopoetic stem cell transplantation, transplantation of solid organs, aspenia, rheumatological-, gastroenterologic-, dermatologic-, neurologic diseases, biologicals during pregnancy and HIV infection are dealt with.These vaccination guidelines, compiled for the first time in Austria, aim to be of practical help for physicians to facilitate and improve vaccination coverage in immunocompromised patients and their household members and contact persons.

Entities:  

Keywords:  Graduation of immunosuppression; biologicals; cancer patients; contraindication; live vaccines; multiple sclerosis; rheumatic disease; timing; vaccination schedules

Mesh:

Substances:

Year:  2016        PMID: 27457874     DOI: 10.1007/s00508-016-1033-6

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  140 in total

Review 1.  Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Charlotte Hua; Thomas Barnetche; Bernard Combe; Jacques Morel
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-07       Impact factor: 4.794

2.  Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab.

Authors:  L B S Gelinck; Y K O Teng; G F Rimmelzwaan; B J F van den Bemt; F P Kroon; J M van Laar
Journal:  Ann Rheum Dis       Date:  2007-10       Impact factor: 19.103

Review 3.  Immune-mediated mechanisms influencing the efficacy of anticancer therapies.

Authors:  Seth B Coffelt; Karin E de Visser
Journal:  Trends Immunol       Date:  2015-04       Impact factor: 16.687

4.  Functional impairment of monocyte-derived dendritic cells in patients with severe chronic kidney disease.

Authors:  Martijn Anton Verkade; Corné Johan van Druningen; Leonard Maria Bernardus Vaessen; Dennis Adriaan Hesselink; Willem Weimar; Michiel Gerardus Henricus Betjes
Journal:  Nephrol Dial Transplant       Date:  2006-09-27       Impact factor: 5.992

5.  [Vaccine-associated paralytic poliomyelitis showing biphasic motor paresis].

Authors:  Mariko Oishi; Motoharu Kawai; Jun-Ichi Ogasawara; Michiaki Koga; Takashi Kanda
Journal:  Rinsho Shinkeigaku       Date:  2012

Review 6.  Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.

Authors:  Leon P McLean; Terez Shea-Donohue; Raymond K Cross
Journal:  Immunotherapy       Date:  2012-09       Impact factor: 4.196

7.  Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis.

Authors:  Michael Kaufman; Gabriel Pardo; Howard Rossman; Marianne T Sweetser; Fiona Forrestal; Petra Duda
Journal:  J Neurol Sci       Date:  2014-03-26       Impact factor: 3.181

8.  Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.

Authors:  Clifton O Bingham; R John Looney; Atul Deodhar; Neal Halsey; Maria Greenwald; Christine Codding; Benjamin Trzaskoma; Flavius Martin; Sunil Agarwal; Ariella Kelman
Journal:  Arthritis Rheum       Date:  2010-01

9.  The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: Case studies.

Authors:  Saloumeh K Fischer; Jihong Yang; Banmeet Anand; Kyra Cowan; Robert Hendricks; Jing Li; Gerald Nakamura; An Song
Journal:  MAbs       Date:  2012-07-23       Impact factor: 5.857

10.  Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.

Authors:  Fiona E McCann; Andrew C Palfreeman; Melanie Andrews; Dany P Perocheau; Julia J Inglis; Peter Schafer; Marc Feldmann; Richard O Williams; Fionula M Brennan
Journal:  Arthritis Res Ther       Date:  2010-06-02       Impact factor: 5.156

View more
  10 in total

Review 1.  Vaccination in Children With Autoimmune Disorders and Treated With Various Immunosuppressive Regimens: A Comprehensive Review and Practical Guide.

Authors:  Geraldine Blanchard-Rohner
Journal:  Front Immunol       Date:  2021-08-02       Impact factor: 7.561

Review 2. 

Authors:  Eva Untersmayr; Elisabeth Förster-Waldl; Michael Bonelli; Kaan Boztug; Patrick M Brunner; Thomas Eiwegger; Kathrin Eller; Lisa Göschl; Katharina Grabmeier-Pfistershammer; Wolfram Hötzenecker; Galateja Jordakieva; Alexander R Moschen; Birgit Pfaller; Winfried Pickl; Walter Reinisch; Ursula Wiedermann; Ludger Klimek; Karl-Christian Bergmann; Randolf Brehler; Natalija Novak; Hans F Merk; Uta Rabe; Wolfgang W Schlenter; Johannes Ring; Wolfgang Wehrmann; Norbert K Mülleneisen; Holger Wrede; Thomas Fuchs; Erika Jensen-Jarolim
Journal:  Allergo J       Date:  2021-08-13

Review 3.  [The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 2: vaccine technologies].

Authors:  Tobias Monschein; Tobias Zrzavy; Micha Löbermann; Alexander Winkelmann; Thomas Berger; Paulus Rommer; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nervenarzt       Date:  2021-07-07       Impact factor: 1.297

Review 4.  Vaccination in Multiple Sclerosis: Friend or Foe?

Authors:  Tobias Zrzavy; Herwig Kollaritsch; Paulus S Rommer; Nina Boxberger; Micha Loebermann; Isabella Wimmer; Alexander Winkelmann; Uwe K Zettl
Journal:  Front Immunol       Date:  2019-08-07       Impact factor: 7.561

5.  Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment.

Authors:  Claudia Bettoni da Cunha-Riehm; Verena Hildebrand; Michaela Nathrath; Markus Metzler; Meinolf Suttorp
Journal:  Front Immunol       Date:  2020-04-17       Impact factor: 7.561

6.  Influenza vaccination uptake and factors influencing vaccination decision among patients with chronic kidney or liver disease.

Authors:  Michael Eder; Haris Omic; Jana Gorges; Florian Badt; Zeljko Kikic; Marcus D Saemann; Allison Tong; David Bauer; Georg Semmler; Thomas Reiberger; Heimo Lagler; Bernhard Scheiner
Journal:  PLoS One       Date:  2021-04-13       Impact factor: 3.240

7.  [Vaccinations].

Authors:  Sebastian Wendt; Henning Trawinski; Corinna Pietsch; Michael Borte; Christoph Lübbert
Journal:  Internist (Berl)       Date:  2021-10-28       Impact factor: 0.743

Review 8.  Vaccination and immunotherapies in neuroimmunological diseases.

Authors:  Alexander Winkelmann; Micha Loebermann; Michael Barnett; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2022-04-06       Impact factor: 44.711

9. 

Authors:  Hans-Jürgen Laws; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Maximilian Christopeit; Jane Hecht; Ulrich Heininger; Inken Hilgendorf; Winfried Kern; Kerstin Kling; Guido Kobbe; Wiebe Külper; Thomas Lehrnbecher; Roland Meisel; Arne Simon; Andrew Ullmann; Maike de Wit; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-05       Impact factor: 1.513

Review 10.  [Travel vaccinations in rheumatic diseases : Specific considerations in children and adults].

Authors:  T Welzel; A Wörner; U Heininger
Journal:  Z Rheumatol       Date:  2020-11       Impact factor: 1.372

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.